Unilens Vision shareholders vote in favor of new incentive stock option plan

Unilens Vision Inc. (OTC Bulletin Board: UVICF; TSX Venture Exchange: UVI) today announced that the shareholders of Unilens Vision Inc. voted in favor of all of the resolutions set out in the Company's Information Circular dated February 26, 2010, as recommended by management. The resolutions approved the continuation of the Company into the State of Delaware, a new incentive stock option plan, the election of Directors, and the appointment of Auditors.  The Company expects to complete the continuation, which will change the Company's jurisdiction of origination from British Columbia, Canada to Delaware, in the coming weeks.

The Company has granted 160,000 options to ten people including employees and directors of the Company under the new incentive stock option plan effective March 25, 2010, all of which are exercisable at US $4.83 per share, being the closing price of the Company's shares on March 25, 2010.  

SOURCE Unilens Vision Inc.

Posted in:

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

Sign in to keep reading

We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free.

or

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.